PT1237559E - Combinacoes farmaceuticas compreendendo um antagonista do receptor p2t e megalatrano - Google Patents

Combinacoes farmaceuticas compreendendo um antagonista do receptor p2t e megalatrano

Info

Publication number
PT1237559E
PT1237559E PT00982033T PT00982033T PT1237559E PT 1237559 E PT1237559 E PT 1237559E PT 00982033 T PT00982033 T PT 00982033T PT 00982033 T PT00982033 T PT 00982033T PT 1237559 E PT1237559 E PT 1237559E
Authority
PT
Portugal
Prior art keywords
megalatran
comprehending
antagonist
receptor
pharmaceutical combinations
Prior art date
Application number
PT00982033T
Other languages
English (en)
Inventor
Dixon John
Humphries Robert
Jarvis Gavin
Kirk Ian
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PT1237559E publication Critical patent/PT1237559E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT00982033T 1999-12-01 2000-11-29 Combinacoes farmaceuticas compreendendo um antagonista do receptor p2t e megalatrano PT1237559E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9904377A SE9904377D0 (sv) 1999-12-01 1999-12-01 Pharmaceutical combinations

Publications (1)

Publication Number Publication Date
PT1237559E true PT1237559E (pt) 2006-10-31

Family

ID=20417947

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00982033T PT1237559E (pt) 1999-12-01 2000-11-29 Combinacoes farmaceuticas compreendendo um antagonista do receptor p2t e megalatrano

Country Status (33)

Country Link
US (2) US20030032618A1 (pt)
EP (2) EP1719526A3 (pt)
JP (1) JP2003515565A (pt)
KR (1) KR100785953B1 (pt)
CN (1) CN1402639A (pt)
AR (1) AR033658A1 (pt)
AT (1) ATE332698T1 (pt)
AU (1) AU781691B2 (pt)
BR (1) BR0016043A (pt)
CA (1) CA2391161C (pt)
CO (1) CO5271717A1 (pt)
CY (1) CY1105211T1 (pt)
CZ (1) CZ300925B6 (pt)
DE (1) DE60029340T2 (pt)
DK (1) DK1237559T3 (pt)
EE (1) EE05127B1 (pt)
ES (1) ES2267591T3 (pt)
HK (1) HK1047893A1 (pt)
HU (1) HU230890B1 (pt)
IL (1) IL149495A0 (pt)
IS (1) IS2841B (pt)
MX (1) MXPA02004871A (pt)
MY (1) MY128896A (pt)
NO (1) NO331215B1 (pt)
NZ (2) NZ530058A (pt)
PT (1) PT1237559E (pt)
RU (1) RU2242232C2 (pt)
SE (1) SE9904377D0 (pt)
SI (1) SI1237559T1 (pt)
SK (1) SK288707B6 (pt)
TW (1) TWI251491B (pt)
WO (1) WO2001039781A1 (pt)
ZA (1) ZA200203707B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7452870B2 (en) 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7115585B2 (en) 2000-08-21 2006-10-03 Inspire Pharmaceuticals, Inc. Compositions for treating epithelial and retinal tissue diseases
US7132408B2 (en) 2000-08-21 2006-11-07 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US6897201B2 (en) 2000-08-21 2005-05-24 Inspire Pharmaceuticals, Inc. Compositions and methods for the treatment of glaucoma or ocular hypertension
DE10064797A1 (de) * 2000-12-22 2002-06-27 Knoll Ag Orale und parenterale pharmazeutische Formulierung, umfassend eine niedermolekulare Thrombininhibitor-Pro-Pharmakon
SE0101932D0 (sv) * 2001-05-31 2001-05-31 Astrazeneca Ab Pharmaceutical combinations
US7435724B2 (en) 2002-02-27 2008-10-14 Inspire Pharmaceutical, Inc. Degradation-resistant mononucleoside phosphate compounds
EP1604669A1 (en) * 2004-06-10 2005-12-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of ATP analogues for treatment of cardiovascular diseases
CN101253179B (zh) * 2005-09-21 2010-12-29 株式会社钟根堂 S-氯吡格雷的树脂酸盐复合物及其制备方法
US20130303477A1 (en) 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
US20120141468A1 (en) 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
US8759316B2 (en) 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US9427448B2 (en) 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
WO2009140092A1 (en) 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
PT2498731T (pt) 2009-11-11 2020-02-21 Chiesi Farm Spa Métodos de tratamento ou prevenção de uma trombose de endoprótese
CN103582480B (zh) 2011-02-09 2016-03-16 医药公司 治疗肺高压的方法
PL2964233T3 (pl) 2013-03-09 2022-04-25 Chiesi Farmaceutici S.P.A. Sposoby leczenia, zmniejszania częstości występowania i(lub) profilaktyki zdarzeń niedokrwiennych
KR20200018481A (ko) 2017-06-23 2020-02-19 키에시 파르마슈티시 엣스. 피. 에이. 체폐동맥 션트 혈전증의 예방 방법

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8826448D0 (en) * 1988-11-11 1988-12-14 Thrombosis Res Inst Improvements in/relating to organic compounds
CA2107667A1 (en) * 1991-04-06 1992-10-07 Anthony Howard Ingall Atp analogues
PL175623B1 (pl) * 1993-02-10 1999-01-29 Astra Pharma Prod N-alkilo-2-podstawione analogi ATP, sposób ich wytwarzania i kompozycja farmaceutyczna je zawierająca
MA23420A1 (fr) * 1994-01-07 1995-10-01 Smithkline Beecham Corp Antagonistes bicycliques de fibrinogene.
SE9404196D0 (sv) * 1994-12-02 1994-12-02 Astra Ab New antithrombotic formulation
PL182680B1 (pl) * 1995-07-11 2002-02-28 Astrazeneca Ab Nowe inhibitory skupiania się płytek krwi
CA2332608C (en) * 1998-06-17 2010-03-23 Bristol-Myers Squibb Company Preventing cerebral infarction through administration of adp-receptor antiplatelet and antihypertensive drugs in combination
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
TWI229674B (en) * 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
US6462021B1 (en) * 2000-11-06 2002-10-08 Astrazeneca Ab Use of low molecular weight thrombin inhibitor
US6696468B2 (en) * 2002-05-16 2004-02-24 Dainippon Pharmaceutical Co., Ltd. (s)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor
US20040067995A1 (en) * 2002-10-02 2004-04-08 Wong Pancras C. Novel combination of a factor Xa inhibitor and clopidogrel
WO2005007191A1 (ja) * 2003-07-16 2005-01-27 Kyowa Hakko Kogyo Co., Ltd. 医薬組成物

Also Published As

Publication number Publication date
AU1910901A (en) 2001-06-12
ES2267591T3 (es) 2007-03-16
SK7502002A3 (en) 2003-02-04
CZ300925B6 (cs) 2009-09-09
RU2002117296A (ru) 2004-01-20
EP1719526A2 (en) 2006-11-08
IS2841B (is) 2013-08-15
IS6398A (is) 2002-05-27
US20060270607A1 (en) 2006-11-30
CN1402639A (zh) 2003-03-12
BR0016043A (pt) 2002-07-23
CO5271717A1 (es) 2003-04-30
EE05127B1 (et) 2009-02-16
EP1719526A3 (en) 2007-04-25
NZ530058A (en) 2005-04-29
CZ20021887A3 (cs) 2002-11-13
NO20022606D0 (no) 2002-05-31
IL149495A0 (en) 2004-03-28
AU781691B2 (en) 2005-06-09
SE9904377D0 (sv) 1999-12-01
KR100785953B1 (ko) 2007-12-14
MXPA02004871A (es) 2002-08-30
TWI251491B (en) 2006-03-21
WO2001039781A1 (en) 2001-06-07
DK1237559T3 (da) 2006-10-30
EP1237559B1 (en) 2006-07-12
PL355841A1 (en) 2004-05-17
RU2242232C2 (ru) 2004-12-20
MY128896A (en) 2007-02-28
NO20022606L (no) 2002-07-11
HU230890B1 (hu) 2018-12-28
NZ518904A (en) 2004-02-27
HUP0203585A3 (en) 2005-01-28
EE200200271A (et) 2003-06-16
US20030032618A1 (en) 2003-02-13
NO331215B1 (no) 2011-11-07
ZA200203707B (en) 2003-10-29
ATE332698T1 (de) 2006-08-15
AR033658A1 (es) 2004-01-07
HUP0203585A2 (hu) 2003-03-28
DE60029340T2 (de) 2007-07-19
JP2003515565A (ja) 2003-05-07
CY1105211T1 (el) 2010-03-03
SK288707B6 (sk) 2019-10-02
SI1237559T1 (sl) 2007-02-28
HK1047893A1 (en) 2003-03-14
CA2391161C (en) 2010-10-05
KR20020069201A (ko) 2002-08-29
DE60029340D1 (de) 2006-08-24
CA2391161A1 (en) 2001-06-07
EP1237559A1 (en) 2002-09-11

Similar Documents

Publication Publication Date Title
PT1237559E (pt) Combinacoes farmaceuticas compreendendo um antagonista do receptor p2t e megalatrano
PT1042301E (pt) Novos derivados de acilguanidina como inibidores da absorcao ossea e como antagonistas do receptor da vitronectina
IS7324A (is) Samrunnin heterósýklísk sukkínímíð efnasambönd oghliðstæður þeirra, stillar fyrir starfsemi kjarnahormónaviðtaka
BRPI0415361A (pt) antagonistas do receptor muscarìnico de acetilcolina
PT1189916E (pt) N-pirazole agonistas do receptor a2a
DE10080052T1 (de) Beratungshilfeverfahren und -einrichtungen
DE69812433D1 (de) Anti-estrogene steroide, pharmazeutische zusammensetzungen und verwendungen davon
EE200100567A (et) Glükokortikoidretseptori modulaatorid
DK1023050T3 (da) Nye formuleringer af farmakologiske midler, fremgangsmåder til fremstillingen deraf og fremgangsmåder til anvendelsen deraf
FI4823U1 (fi) Muunnetulla tavalla vapauttava lääkeformulaatio
DK1221952T3 (da) Anvendelse af en antagonist til centrale cannaboidreceptorer med henblik på fremstilling af lægemidler
NO993350D0 (no) Vitronectin-reseptor-antagonister
DE50010609D1 (de) Sport-trainings-vorrichtung sowie sport-trainings-system
DE60114413D1 (de) Substituierte 1-aminoalkyl-lactame und deren verwendung als muscarinrezeptor-antagonisten
PT1230230E (pt) Derivados de indeno-di-hidrotiazole sua preparacao e sua utilizacao como medicamentos anorexigenico
TR199701645A3 (tr) Vitronektin reseptör antagonistleri,bunlarin imalati ve kullanimi
NO20001514D0 (no) Vitronectin-reseptor-antagonist
DK1275397T3 (da) Lægemiddel til lokal anvendelse
ATE305920T1 (de) Bradykinin receptorantagoniste
NO20013997D0 (no) Reseptoranalyse
BRPI0412716A (pt) antagonistas de receptor muscarìnico de acetilcolina
NO20004503D0 (no) Vitronectin-reseptor-antagonister
NO20001515D0 (no) Vitronektin reseptor-antagonist
BRPI0412679A (pt) antagonistas de receptor muscarìnico de acetilcolina
ATE277043T1 (de) Vitronectin rezeptor antagonist